Nubia Capital, a US-based early-stage venture firm investing in African startups, has announced a strategic investment in Fertitude, a fast-growing company building AI-powered infrastructure for women’s health across emerging markets and the global diaspora. The investment signals renewed institutional confidence in Africa’s healthtech ecosystem and growing conviction in AI-driven preventive health infrastructure.
In a recent LinkedIn post, Davidson Oturu, Partner at Nubia Capital, described Fertitude as a platform where women can track fertility and cycle health with AI-powered tools, connect with human specialists, and receive guidance discreetly, anytime, anywhere. Beyond access, what stands out is the shift from simple tracking to continuous monitoring and decision support between clinic visits, a gap that remains largely unaddressed across the healthcare ecosystem.
While Fertitude began with fertility and hormonal health, its broader ambition is to become an intelligence layer for women’s health across life stages, from first periods to conception, pregnancy, postpartum recovery, perimenopause, menopause, and long-term hormonal wellbeing.
Globally, more than 400 million women already use digital tools to track their cycles. The demand is established. Yet most tools stop at logging symptoms. Women experience Fertitude as an app that helps them take charge of their health between clinic visits, but behind the consumer interface, the platform combines longitudinal reproductive health data, AI-driven risk modeling, and clinically informed logic to:
• Flag risk earlier
• Explain patterns in simple language
• Guide appropriate next steps
• Route users to real clinicians when needed
Since launch, Fertitude has grown to 15,000+ users across 39 countries, tripling its user base in the last quarter with approximately 60% month-over-month growth. The platform maintains strong engagement, with tens of thousands of symptom logs recorded and over 200,000 AI-assisted interactions through its assistant, “Kiki.” Growth to date has been achieved with minimal paid marketing, reflecting strong organic pull and habit-forming use cases.
The founding team combines clinical expertise and deep product experience in emerging markets. CEO Dr. Kieva Chris-Amusan is a medical doctor and repeat founder with a decade of experience scaling products used by millions of women globally, alongside lived experience navigating Polycystic Ovarian Syndrome, a common condition estimated to affect about 1 in every 10 women. CTO Ken Ovienadu previously helped build two venture-backed healthtech platforms, Google- and YC-backed, with $46M+ raised combined, and now leads Fertitude’s engineering and product development.
Fertitude is already generating subscription and marketplace revenue, while expanding strategic distribution through corporate and public-sector partnerships. Beyond consumer subscriptions, the company has a clear path to high-margin B2B enterprise revenue through structured data partnerships, leveraging its proprietary longitudinal reproductive health dataset drawn from diverse and underrepresented populations.
The women’s digital health market is projected to exceed $100B globally over the coming decade, with Africa representing a ~$24B opportunity. Yet emerging markets remain significantly underserved and underrepresented in global health datasets, a structural gap that is beginning to attract institutional and regulatory attention. Fertitude is actively addressing this through ethical AI development and responsible data governance. The company is NDPC-compliant and prioritises strong data protection standards as it builds one of the most comprehensive reproductive health datasets from emerging markets.
As global attention and funding in women’s health accelerate, pharma companies, insurers, employers, and research institutions increasingly require high-quality, ethically sourced real-world data to support prevention programs, drug development, clinical research, and the training of more inclusive AI models. This positions Fertitude to tap into the adjacent real-world health data and analytics market, projected to exceed $166B by 2030.
As Davidson Oturu noted in his announcement, women’s health is not a niche category. It represents over 50% of the population, and an infrastructure opportunity hiding in plain sight.
Fertitude sits at the intersection of prevention, personalisation, and data intelligence. As health systems, employers, insurers, and pharma increasingly shift toward early detection and continuous monitoring, the need for longitudinal, real-world reproductive data will only intensify. Platforms that combine user trust, engagement, and structured intelligence will define the next phase of women’s health infrastructure, particularly in emerging markets where clinical-grade longitudinal data remains scarce.
The investment from Nubia Capital forms part of Fertitude’s ongoing pre-seed round, as the company continues to strengthen its product capabilities, expand enterprise partnerships, and deepen its data infrastructure across Africa and the global diaspora. Active discussions with other aligned institutional partners are underway as the round progresses.
Learn more: www.fertitude.com
